Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07333482 · ClinicalTrials.gov registry record · NA
Flourish: Exploring the Early Infant Gut Microbiome
A NA study of Eczema and Gut Microbiome, sponsored by Seeding.
- Recruiting
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT07333482 is a NA study of Eczema and Gut Microbiome that is actively recruiting participants, run by Seeding. The registered enrollment target is 250 participants, above the 198-participant average among 29 other Eczema trials with a reported enrollment target (26% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07333482, a NA study of Eczema and Gut Microbiome, is actively recruiting participants, sponsored by Seeding.
- RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn whether microbiome analysis, education, and personalized recommendations can improve gut health and reduce early markers of immune-related conditions in infants aged 0-3 months delivered via Cesarean section. The study aims to determine whether these interventions can increase beneficial bacteria, decrease C-section-associated microbiome signatures, reduce opportunistic pathogens, and improve functional potential for HMO digestion and SCFA production. The study also seeks to assess whether improvements in microbiome composition are associated with a reduced prevalence of early atopic symptoms. Researchers will compare three groups: a full intervention arm that receives microbiome reports, coaching, personalized recommendations, and educational materials; a limited intervention arm that receives simplified reports and basic recommendations; and a control arm that receives no results until study completion. This design allows evaluation of both a comprehensive intervention and a more scalable, minimal-results model. Participants will: 1. Provide six microbiome stool samples over a 24-month period. 2. Provide additional small stool samples at two timepoints for exploratory metabolomic analysis. 3. Receive microbiome reports and guidance according to their assigned study arm. 4. Complete surveys on infant health history, symptoms, diet, and environmental exposures. 5. Participate in standardized eczema assessment(s) administered by a Nurse Practitioner and evaluated by a Pediatric Allergy Specialist if any symptoms are reported. This study seeks to demonstrate that targeted microbiome support can positively shift gut microbial development in C-section infants and may reduce risks linked to the early stages of the atopic march. Findings may inform scalable strategies for delivering microbiome-based support in early life and improve long-term health outcomes for this high-risk population.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Tailored Recommendations
- BEHAVIORAL Consult Call
- BEHAVIORAL Educational Email Series
Study Locations (1)
Texas
- Seeding Labs INC - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2026-01-31 |
| Est. Completion | 2028-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07333482
The ClinicalTrials.gov registry entry for NCT07333482 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 198-participant average among 29 other Eczema trials with a reported enrollment target (26% higher). The listed sponsor is Seeding, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Eczema appearing as the primary indexed condition, and to 3 interventions - of which Tailored Recommendations is the first listed.
NCT07333482 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07333482 about?
NCT07333482 is a clinical study titled "Flourish: Exploring the Early Infant Gut Microbiome". The goal of this clinical trial is to learn whether microbiome analysis, education, and personalized recommendations can improve gut health and reduce early markers of immune-related conditions in infants aged 0-3 months delivered via Cesarean section. The study aims to determine whether these inter...
What is the current status of trial NCT07333482?
This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2026-01-31. Estimated completion is 2028-09.
What conditions does trial NCT07333482 study?
This clinical trial studies the following conditions: Eczema, Gut Microbiome, Microbiome, Microbiota.
What interventions are being tested in trial NCT07333482?
The interventions under investigation include: Tailored Recommendations (DIETARY_SUPPLEMENT), Consult Call (BEHAVIORAL), Educational Email Series (BEHAVIORAL).
Who is sponsoring clinical trial NCT07333482?
This trial is sponsored by Seeding, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07333482 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eczema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Infant Restore: Efficacy of Microbiome Analysis and Education
ACTIVE NOT RECRUITING · NA
-
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
COMPLETED · NA
-
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
COMPLETED · NA
-
Joovvin' for Your Skin Health Study
COMPLETED · NA
-
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.